Clinical course and management of children with IgA vasculitis with nephritis.
Chronic kidney disease
Glomerulonephritis
Henoch-Schönlein purpura
Nephrology
Vasculitis
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
05
01
2023
accepted:
04
05
2023
revised:
25
04
2023
medline:
22
9
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
IgA vasculitis is the most common vasculitis in children and is often complicated by acute nephritis (IgAVN). Risk of chronic kidney disease (CKD) among children with IgAVN remains unknown. This study aimed to describe the clinical management and kidney outcomes in a large cohort of children with IgAVN. This observational cohort study used the PEDSnet database to identify children diagnosed with IgAV between January 1, 2009, and February 29, 2020. Demographic and clinical characteristics were compared among children with and without kidney involvement. For children followed by nephrology, clinical course, and management patterns were described. Patients were divided into four categories based on treatment: observation, renin-angiotensin-aldosterone system (RAAS) blockade, corticosteroids, and other immunosuppression, and outcomes were compared among these groups. A total of 6802 children had a diagnosis of IgAV, of whom 1139 (16.7%) were followed by nephrology for at least 2 visits over a median follow-up period of 1.7 years [0.4,4.2]. Conservative management was the most predominant practice pattern, consisting of observation in 57% and RAAS blockade in 6%. Steroid monotherapy was used in 29% and other immunosuppression regimens in 8%. Children receiving immunosuppression had higher rates of proteinuria and hypertension compared to those managed with observation (p < 0.001). At the end of follow-up, 2.6 and 0.5% developed CKD and kidney failure, respectively. Kidney outcomes over a limited follow-up period were favorable in a large cohort of children with IgAV. Immunosuppressive medications were used in those with more severe presentations and may have contributed to improved outcomes. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
IgA vasculitis is the most common vasculitis in children and is often complicated by acute nephritis (IgAVN). Risk of chronic kidney disease (CKD) among children with IgAVN remains unknown. This study aimed to describe the clinical management and kidney outcomes in a large cohort of children with IgAVN.
METHODS
This observational cohort study used the PEDSnet database to identify children diagnosed with IgAV between January 1, 2009, and February 29, 2020. Demographic and clinical characteristics were compared among children with and without kidney involvement. For children followed by nephrology, clinical course, and management patterns were described. Patients were divided into four categories based on treatment: observation, renin-angiotensin-aldosterone system (RAAS) blockade, corticosteroids, and other immunosuppression, and outcomes were compared among these groups.
RESULTS
A total of 6802 children had a diagnosis of IgAV, of whom 1139 (16.7%) were followed by nephrology for at least 2 visits over a median follow-up period of 1.7 years [0.4,4.2]. Conservative management was the most predominant practice pattern, consisting of observation in 57% and RAAS blockade in 6%. Steroid monotherapy was used in 29% and other immunosuppression regimens in 8%. Children receiving immunosuppression had higher rates of proteinuria and hypertension compared to those managed with observation (p < 0.001). At the end of follow-up, 2.6 and 0.5% developed CKD and kidney failure, respectively.
CONCLUSIONS
Kidney outcomes over a limited follow-up period were favorable in a large cohort of children with IgAV. Immunosuppressive medications were used in those with more severe presentations and may have contributed to improved outcomes. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 37316676
doi: 10.1007/s00467-023-06023-8
pii: 10.1007/s00467-023-06023-8
pmc: PMC10514113
mid: NIHMS1925477
doi:
Substances chimiques
Immunoglobulin A
0
Types de publication
Observational Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3721-3733Subventions
Organisme : NIDDK NIH HHS
ID : P50 DK114786
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Davin JC, Coppo R (2014) Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol 10:563–573
doi: 10.1038/nrneph.2014.126
pubmed: 25072122
Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920
doi: 10.1136/adc.2005.074641
pubmed: 15871983
pmcid: 1720564
Goldstein AR, White RH, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 339:280–282
doi: 10.1016/0140-6736(92)91341-5
pubmed: 1346291
Delbet JD, Hogan J, Aoun B, Stoica I, Salomon R, Decramer S, Brocheriou I, Deschênes G, Ulinski T (2017) Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents. Pediatr Nephrol 32:1193–1199
doi: 10.1007/s00467-017-3604-9
pubmed: 28204946
Shenoy M, Bradbury MG, Lewis MA, Webb NJ (2007) Outcome of Henoch-Schonlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722
doi: 10.1007/s00467-007-0557-4
pubmed: 17647023
Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet 360:666–670
doi: 10.1016/S0140-6736(02)09835-5
pubmed: 12241872
Foster BJ, Bernard C, Drummond KN, Sharma AK (2000) Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 136:370–375
doi: 10.1067/mpd.2000.103448
pubmed: 10700695
Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243
doi: 10.1007/s004670050446
pubmed: 9630046
Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, Jahnukainen T, Rajantie J, Ormala T, Nuutinen M (2011) Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol 26:2159–2166
doi: 10.1007/s00467-011-1919-5
pubmed: 21626222
Tarshish P, Bernstein J, Edelmann CM Jr (2004) Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56
doi: 10.1007/s00467-003-1315-x
pubmed: 14634864
Koskela M, Jahnukainen T, Enden K, Arikoski P, Kataja J, Nuutinen M, Ylinen E (2019) Methylprednisolone or cyclosporine a in the treatment of Henoch-Schonlein nephritis: a nationwide study. Pediatr Nephrol 34:1447–1456
doi: 10.1007/s00467-019-04238-2
pubmed: 30955086
Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, Milov DE, Vieland VJ, Wolf BA, Yu FB, Kahn MG (2014) PEDSnet: a National Pediatric Learning Health System. J Am Med Inform Assoc 21:602–606
doi: 10.1136/amiajnl-2014-002743
pubmed: 24821737
pmcid: 4078288
(2012) Health information technology: standards, implementation specifications, and certification criteria for electronic health record technology, 2014 edition; revisions to the permanent certification program for health information technology. Final rule. Fed Regist 77:54163–54292
Simon TD, Cawthon ML, Stanford S, Popalisky J, Lyons D, Woodcox P, Hood M, Chen AY, Mangione-Smith R (2014) Pediatric medical complexity algorithm: a new method to stratify children by medical complexity. Pediatrics 133:e1647-1654
doi: 10.1542/peds.2013-3875
pubmed: 24819580
pmcid: 4035595
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
doi: 10.1681/ASN.2008030287
pubmed: 19158356
pmcid: 2653687
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN, (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904
doi: 10.1542/peds.2017-1904
pubmed: 28827377
Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L (2006) Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am J Kidney Dis 47:993–1003
doi: 10.1053/j.ajkd.2006.02.178
pubmed: 16731294
Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena FP (1997) Long-term prognosis of Henoch-Schonlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schonlein purpura. Nephrol Dial Transplant 12:2277–2283
doi: 10.1093/ndt/12.11.2277
pubmed: 9394311
Edstrom Halling S, Soderberg MP, Berg UB (2010) Predictors of outcome in Henoch-Schonlein nephritis. Pediatr Nephrol 25:1101–1108
doi: 10.1007/s00467-010-1444-y
pubmed: 20174831
Koskimies O, Mir S, Rapola J, Vilska J (1981) Henoch-Schonlein nephritis: long-term prognosis of unselected patients. Arch Dis Child 56:482–484
doi: 10.1136/adc.56.6.482
pubmed: 7259283
pmcid: 1627458
Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schonlein nephritis. Pediatr Nephrol 22:64–70
doi: 10.1007/s00467-006-0278-0
pubmed: 17024391
Scharer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F (1999) Clinical outcome of Schonlein-Henoch purpura nephritis in children. Pediatr Nephrol 13:816–823
doi: 10.1007/s004670050707
pubmed: 10603128
(2012) Chapter 11: Henoch-Schonlein purpura nephritis. Kidney Int Suppl (2011) 2:218–220
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753–779
doi: 10.1016/j.kint.2021.05.015
pubmed: 34556300
Shi D, Chan H, Yang X, Zhang G, Yang H, Wang M, Li Q (2019) Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis. PLoS One 14:e0223218
doi: 10.1371/journal.pone.0223218
pubmed: 31574112
pmcid: 6772070
Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D (2002) Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 13:1271–1278
doi: 10.1097/01.ASN.0000013883.99976.22
pubmed: 11961015